PD-1 inhibitor combined with ablation in liver metastasis: A retrospective, multicenter study.

• DOI: 10.1200/jco.2024.42.16_suppl.e14644
• Publication Date: 2024-06-04T19:44:01Z
• Authors: Dengyao Liu; Tao Huang; Zhanguo Sun; Pan Hu; Tao Zhu; Dongcun Huang; Bingchen Xu; Dechao Jiao; Fujun Zhang; Letao Lin
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e14644 Background: This study aimed to retrospectively evaluate the efficacy of ablation combined with programmed cell death protein 1 (PD-1) inhibitor versus PD-1 monotherapy in patients liver metastasis. Methods: We enrolled metastasis who received therapy or without at three medical institutions between January 2017 and September 2022. Progression-free survival (PFS) 1-year rates were compared after propensity score matching. Additionally, intrahepatic extrahepatic lesion progression treatment-related adverse events recorded during follow-up. Finally, prognostic factors for group analyzed. Results: included 172 classified them into (n = 86 each) groups. Patients had better median PFS than those group. Combined was an independent factor univariate multivariate analyses. New lesions constituted main pattern progression, showing significantly lower but similar rates. Adverse associated inhibitors comparable two 8 (9.3%) experienced ablation-related complications. However, neither univariate, nor analyses revealed predictive Conclusions: Ablation a superior improving